Jennifer Vaughn, MD, discusses how value-based care in hematology should consider cost and financial toxicity, as well as valuable patient experience.
Oral chemotherapy agents offer patients a reprieve from fees and facility costs, but they also put the cost of vital medications on the patient, highlighting an area of need, discusses Jennifer Vaughn, MD, assistant professor in the division of hematology at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute.
Transcript
What strides are being made to improve and expand access to value-based care in hematology, and what more needs to be done?
Hematology, in itself, is a unique space in that we've had a lot of very rapid development and very effective, but also very expensive therapies, over the last couple of decades. I think some particular spaces that we really need to think about how we're going to create a value-based care experience for our patients are in the aggressive treatments of hematologic malignancies, with modalities such as stem cell transplant, CAR T therapies, gene therapy.
I sit in our classical hematology section within our division and work closely with hemophilia and sickle cell disease physicians, who very soon will have access to these types of therapies for their patients. And obviously they carry with them a lot of cost, so as we're planning how we're going to provide these treatments, thinking about other ways we can streamline those processes and provide the supportive care that the patients are going to need in order to truly make the experience a valuable one, both from the financial standpoint but also from the viewpoint of the patient.
The other interesting component of hematology and value-based care that I feel very passionate about, and have done a little research in, is the concept of financial toxicity that patients experience when we are administering oral chemotherapy agents. In hematology, our use of oral agents for treatment of malignant diseases is increasing very rapidly, and it's really shifted the responsibility of administering drugs from the clinic and the infusion center to the patient and the caregiver.
It does save costs in that it avoids all of those fees from the facility, the infusion center fees, but what it does then is it places the cost in the hands of the patient as well. I know many of my patients have been faced with fairly large copays to pay for drugs that they need for life-sustaining therapy, simply because their insurance coverage is done in a different way so that they have a lot of costs for orally administered drugs, where they might not have that cost for infusions.
[We’re] really looking into how patients are being affected by this and how we can help mitigate those costs. Obviously, lots of health care systems have systems in place that can support patients through getting grants and assistance from drug companies and things of that nature. I've talked to many patients who say even the process of going through those applications is extremely anxiety provoking and really does impact their quality of life.
From that standpoint, not only are they having to deal with this diagnosis that's overwhelming, but now they're dealing with paperwork and fear that they may lose resources of their own in order to pay for their treatment. I think that's a real area that we need to be thinking about as we create value-based care programs in hematology itself.
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Health Equity and Access Weekly Roundup: April 27, 2024
April 27th 2024Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.
Read More
CMS' 340B Repayment Proposal May Harm Vulnerable Hospitals, Reward Those With Higher Revenues
April 26th 2024The 340B hospitals not receiving an offsetting lump-sum payment from CMS following 2018-2022 cuts later ruled unlawful are disproportionately rural, publicly owned, and nonacademic, according to a new study.
Read More